摘要
目的:观察布地奈德雾化吸入治疗慢性阻塞性肺疾病(COPD)的效果。方法选取我院呼吸科门诊于2014年1月~2015年1月收治的100例COPD患者作为研究样本,采用便利抽样法将其分为对照组与观察组,每组各50例患者,对照组给予吸氧、止咳、解痉、抗炎、纠正酸碱以及水电解质失衡等常规治疗,观察组在常规治疗的基础上联合布地奈德雾化吸入,治疗后对比两组患者的第1秒用力呼气容积(FEV1)、FEV占预计值百分比(FEV1%pred)以及用力肺活量(FVC),并对两组治疗期间的不良反应发生情况进行对比分析。结果(1)治疗后,观察组的FEV1、FEV1%pred以及FVC均明显优于对照组,差异具有统计学意义,P<0.05。(2)治疗期间,观察组共发生嗜睡1例、恶心呕吐3例、腹泻1例,不良反应发生率为10%;对照组共发生嗜睡2例、腹泻2例,不良反应发生率为8%,两组之间比较无明显差异,差异不具有统计学意义,P>0.05。结论在COPD患者的治疗中联合布地奈德雾化吸入能够有效提高患者的肺功能,用药安全性高。
Objective To observe the effect of budesonide inhalation in the treatment of chronic obstructive pulmonary disease (COPD). Methods 100 cases of COPD patients admitted to our hospital from January 2014 to January 2015 were selected as the research sample and were divided into control group and observation group by using convenience sampling method, 50 cases in each group. Control group was given about oxygen inhalation, cough, antispasmodic, anti-inlfammatory, correction of acid-base and water solution of mass imbalance and other conventional treatment, observation group in the conventional treatment based on combined with Budesonide aerosol inhalation treatment, to compare two groups of patients in the ifrst second forced expiratory volume (FEVl), FEVl%pred, forced vital capacity (FVC) and the treatment of adverse reaction were compared and analyzed. Results (1) after treatment, observation group of FEVl, FEVl%pred and FVC were signiifcantly better than the control group, with statistical signiifcance, P〈0.05. (2) during the treatment, the observation group a total of sleepiness in 1 cases, nausea and vomiting in 3 cases, 1 case of diarrhea, adverse reactions occur rate is 10%;control group there were somnolence (2 cases), 2 cases of diarrhea, adverse reactions occur rate is 8%, between the two groups no signiifcant difference does not have statistical significance (P 〉 0.05). Conclusion In the treatment of patients with chronic obstructive pulmonary disease (COPD) combined with budesonide inhalation can effectively improve the pulmonary function of the patients, drug safety, as chronic obstructive pulmonary disease (COPD) is the treatment of choice for drug promotion.
出处
《中国继续医学教育》
2016年第21期150-151,共2页
China Continuing Medical Education
关键词
布地奈德
慢性阻塞性肺疾病
雾化吸入
Budesonide
Chronic obstructive pulmonary disease
Aerosol inhalation